Form 4 for ELOX Eloxx Pharmaceuticals, Inc.
Accepted 2025-01-28 00:00:00 ET · period of report 2025-01-24 · accession 0001104659-25-006781 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-28 | 2025-01-24 | ELOX | Walts Alan Edmund | Dir | M - OptEx | $0.00 | +3,750 | 16.7K | +29% | $0 |
| D | 2025-01-28 | 2025-01-24 | ELOX | Walts Alan Edmund | Dir | M - OptEx | $0.00 | -3,750 | 3,750 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-24 | M | A | 3,750 | $0.00 | 16,692 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2025-01-24 | M | D | 3,750 | $0.00 | 3,750 | D | — · — to — | 3,750 Common Stock | (F2) The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |